Jianfeng Group Lin2017 -003 Announcement on Foreign Investment of Subsidiates
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 公告编号:2017-003
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于子公司对外投资的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l 交易简要内容:本公司控股子公司浙江尖峰药业有限公司(以下简称:尖峰药业)拟分四期对北京慧宝源生物技术股份有限公司(以下简称:北慧生物、标的公司、公司)进行投资,其中:第一期出资8000万元,以每股4元的价格增资2000万股;第二期出资8600万元,以每股4.3元的价格增资2000万股,另出资3010万元以每股4.3元的价格受让桂林商源植物制品有限公司(以下简称:桂林商源)出让的北慧生物700万股;第三、第四期各增资1400万股,增资价格以届时的北慧生物的评估值为基础协商确定。若增资和股权转让全部完成,尖峰药业将持有北慧生物7500万股(占50.68%的股权,股权比例的计算未考虑引入其他投资者的情况)。
l 本次交易不构成关联交易
l 本次交易不构成重大资产重组
l 本次股权收购和增资事项经公司董事会审议后无需提交股东大会审议批准。
一、对外投资概述
(一)2017年02月28日,本公司控股子公司浙江尖峰药业有限公司与桂林商源植物制品有限公司、北京慧宝源企业管理有限公司(以下简称:北慧企管)、北京慧宝源生物技术股份有限公司签订了《关于北京慧宝源生物技术股份有限公司之增资和股权转让协议》(以下简称:《主协议》)、《业绩承诺补偿协议》,拟以北京慧宝源生物技术股份有限公司及其控股子公司广西慧宝源医药科技有限公司(以下简称:广慧科技)为平台共同合作开展新药研发、药品生产经营业务的合作。
尖峰药业拟以增资和股权转让的方式,分四期对北慧生物进行投资,其中:第一期出资8000万元,以每股4元的价格对北慧生物增资2000万股;第二期出资8600万元,以每股4.3元的价格对北慧生物增资2000万股,另出资3010万元以每股4.3元的价格受让桂林商源出让的北慧生物股权700万股;第三、第四期各对北慧生物增资1400万股,增资价格以届时各方共同认可并聘请的具有证券从业资格的资产评估机构进行评估,以评估结果为基础协商确定。若增资和股权转让全部完成,尖峰药业将持有北慧生物7500万股(占50.68%的股权,股权比例的计算未考虑引入其他投资者的情况)。
第一、二期的增资和股权转让价格以北京北方亚事资产评估事务所出具的《浙江尖峰药业有限公司拟投资而涉及的北京慧宝源生物技术有限公司股东全部权益价值评估报告》(北方亚事评报字【2016】第01-610号)为基础,以及考虑新药研发进程和《业绩承诺补偿协议》等因素,经交易各方充分沟通,谈判确定。
(二)董事会审议情况
2017 年2月28日,公司以通信方式召开了第九届董事会第十次会议,公司现有八名董事全部参加了会议,经审议与表决,董事会以8票同意、0票反对、0票弃权审议并通过了该事项。独立董事发表了独立意见。
(三)根据上海证券交易所《股票上市规则》和公司《章程》等有关规定,公司本次对外投资属董事会权限范围,无需提交股东大会审议。该合作事项不属于关联交易,也不构成《上市公司重大资产重组管理办法》规定的重大资产重组情况。
二、合作各方的基本情况
(一)桂林商源植物制品有限公司
1、企业名称:桂林商源植物制品有限公司
2、企业性质:有限责任公司(外商合资)
3、注册地:桂林灵川八里街开发区
4、注册日期:2003年10月23日
5、主要办公地点:广西省桂林市八里街开发区灵川大道33号
6、法定代表人:詹姆斯 周
7、注册资本:捌万美元整
8、经营范围:生产、销售植物脱水制品(涉及前置许可的项目除外)。(依法须经批准的项目,经相关部门批准后方可开展经营活动。)
9、主要股东:
|
序号 |
股东名称或姓名 |
出资额(万美元) |
出资比例 |
|
1 |
詹姆斯 周 |
4.4 |
55% |
|
2 |
周文迪 |
3.6 |
45% |
注:詹姆斯 周和周文迪是夫妻关系。
10、截至2016年底,桂林商源的资产总额10270.36万元、资产净额4527.59万元,2016年度的营业收入0万元、净利润-13.08万元,该财务数据未经审计。
(二)北京慧宝源企业管理有限公司
1、企业名称:北京慧宝源企业管理有限公司
2、企业性质:其他有限责任公司
3、注册地:北京市海淀区上地信息路2号(北京实创高科技发展总公司2-2号D栋)810
4、注册日期:2010年11月18日
5、主要办公地点:北京市海淀区上地信息路2号(北京实创高科技发展总公司2-2号D栋)810
6、法定代表人:周詹姆斯(与桂林商源的法定代表人詹姆斯 周为同一人)
7、注册资本:5000万元
8、经营范围:企业管理(企业依法自主选择经营项目,开展经营活动;)。(依法须经批准的项目,经相关部门批准后依批准的内容开展经营活动;不得从事本市产业政策禁止和限制类项目的经营活动。)
9、主要股东:
|
序号 |
股东名称或姓名 |
出资额(万元) |
出资比例 |
|
1 |
桂林商源植物制品有限公司 |
2550 |
51% |
|
2 |
王志强 |
1450 |
29% |
|
3 |
王绍峥 |
1000 |
20% |
10、截至2016年底,北慧企管的资产总额7653.85万元、资产净额3750.17万元,2016年度的营业收入0万元、净利润-614.36万元,该财务数据未经审计。
三、合作标的基本情况
(一)标的公司的基本情况
1、企业名称:北京慧宝源生物技术股份有限公司
2、企业性质:其他股份有限公司(非上市)
3、注册地:北京市海淀区开拓路5号A区四层A407、A408室
4、注册日期:2011年07月15日
5、主要办公地点:北京市昌平区生命园路20号院7号楼402室
6、法定代表人:周詹姆斯(与桂林商源的法定代表人詹姆斯 周为同一人)
7、注册资本:8000万元
8、经营范围:技术推广、技术转让、技术咨询、技术服务;医学研究与试验发展;技术进出口。
主要通过其子公司广慧科技开展医药产品的生产和销售业务,广慧科技成立于2013年3月,注册资本20000万元(其中北慧生物占75%、广西中马园区产业平台投资有限公司占25%),住所:中马钦州产业园区中马大街1号,其新建的生产基地设在中国-马来西亚钦州产业园,占地214.46亩,拥有渗漉车间、酊剂车间、固体制剂车间、液体制剂车间等多个剂型的生产车间已基本建成(总建筑面积65378.44 ㎡),目前已经进入GMP认证阶段,待通过GMP认证后可投入生产。广慧科技主要从事医药技术开发研究;医药建设项目投资、咨询;颗粒剂、中药前处理和提取、合剂(口服液)、糖浆剂、酊剂(内服、外用)、搽剂、酒剂、片剂生产、销售;新药技术的引进等。2016年广慧科技通过受让药品相关技术的方式,目前已经拥有以中成药制剂为主的77个药品批文,主要产品有:藿香正气水、十滴水、陈香露白露片、复方珍珠解毒口服液、益肝明目口服液等。公司拥有较强的对外合作及新药研发能力,获得了美国耶鲁大学和佐治亚大学研究基金会股份有限公司的“曲沙他滨”抗癌结构专利、治疗方法和全球商业化开发授权;“克来夫定”抗乙肝病毒的中国商业化开发授权;“克来夫定”抗癌结构专利、治疗方法及抗癌全球商业开发优先权。2016年8月,注射用“曲沙他滨”抗肝癌获得了国家食品药品监督管理局颁发的《药物临床试验批件》(批件号:2016L07060),目前正在进行一期临床前的准备工作。
(1)曲沙他滨
曲沙他滨是由美国耶鲁大学研发的抗肿瘤胞苷类似物,国内外都未有上市,美国SHIRE公司曾进行过适应症为多种实体肿瘤和血液恶性肿瘤的I期/II期临床研究,采用各种剂量方案,进行了曲沙他滨单独给药或与其它化疗药物联合给药,获得了充分的人体暴露量和安全性数据,后由于在血液恶性肿瘤的三期临床试验中与现有类似的产品疗效相似及SHIRE公司产品战略的从新定位,停止了该药品的临床研究。后续研究发现曲沙他滨对肝癌和乙肝病毒具有双重抑制作用,对缺氧环境下的实体瘤更有效。
(2)克来夫定
克来夫定是耶鲁大学郑永齐教授实验室发明的一种具有抗乙肝病毒活性的新型嘧核苷类似物,是继拉米夫定后的第III代抗乙肝药。已在韩国、泰国、菲律宾获得批准上市。克来夫定具有显著的病毒抑制效应及肝脏生化改善作用,在治疗后6个月时仍出现显著持久效应(持久效应是至关重要的优点,因大多数乙肝病人需要长期治疗),具有明显的控制病毒效果。
9、主要股东:
|
序号 |
股东名称 |
出资额(万元) |
出资比例(%) |
|
1 |
桂林商源 |
57,437,300 |
71.80 |
|
2 |
何龙飞 |
10,160,000 |
12.70 |
|
3 |
北慧企管 |
10,000,000 |
12.50 |
|
4 |
其他14名自然人股东 |
2,402,700 |
3.00 |
(二)截至2015年年底,经具有证券、期货从业资格的中审华寅五洲会计师事务所审计,北慧生物的资产总额28501.85万元、负债总额24467.12万元、归属于母公司股东权益4034.73万元,2015年度的营业收入80万元、归属于母公司所有者净利润-537.39万元。
截至2016年末,北慧生物的资产总额33679.56万元、负债总额20563.34万元、归属于母公司股东权益9923.20万元。2016年度的营业收入2609万元、归属于母公司所有者净利润-1314.63万元。2016年的财务数据未经审计。
(三)交易标的评估情况
本次交易委托具有证券从业资格的北京北方亚事资产评估事务所对北慧生物进行评估。北京北方亚事资产评估事务所出具了《浙江尖峰药业有限公司拟投资而涉及的北京慧宝源生物技术股份有限公司股东全部权益价值评估报告》(北方亚事评报字【2016】第01-610号),评估价值为50,545万元,评估基准日为2016年6月30日。
本次评估主要采用收益法对标的公司进行评估,收益法是通过估算被评估企业经济寿命期内预期收益并以适当的折现率折算成现值,以此确定评估对象价值的一种评估方法。即以企业未来年度内产生的自由现金流量作为依据,以适当折现率折现后加总计算得出企业经营性资产价值,然后再加上溢余资产价值、非经营性资产价值,减去有息债务得出股东全部权益价值。
本次评估的结论:列入本次评估范围的北慧生物的账面价值为:资产总额 33,991.57万元,负债总额 19,233.16万元,净资产额10,250.11万元。收益法评估结果为基于被评估单位的盈利预测,股东全部权益的评估值为人民币伍亿零伍佰肆拾伍万元整(RMB50545万元),评估增值 40294.89万元,增值率393.12%。
本次收益发评估的主要假设包括:
<一>假设北慧生物的管理层是负责的,其经营完全遵守现行所有相关的法律和法规;
<二>假设北慧生物之资产在2016年6月30日后继续以目前的经营范围、方式在合理投入的基础上持续经营,企业能够保留并吸引有能力的管理人员、关键人才、技术人员以支持企业向前发展;
<三>北慧生物所在的地区及中国的社会经济环境不产生大的变更,除已出台的政策之外,在可以预见的将来,中国的宏观经济政策趋向平稳,税收、利率、物价水平等基本稳定,相关产业按照发展规划顺利实施,整个国民经济持续稳定,健康发展的态势保持不变;
<四>未来收益预测是在对企业以前年度的经营和管理能力分析基础上产生的,本次评估以企业能够维持或提高现有管理水平和经营水平为假设前提。对企业未来因重大决策或管理原因导致企业效益出现大幅波动或超出预测范围的情况,不在本次评估影响范围内;
<五>假设公司当前投入资产都能够按照规划时间顺利完工并投入运营,企业未来经营发展按照企业的整体发展规划顺利实施并基本实现预期目标;
<六>假设企业会计政策与核算方法无重大变化;
<七>本次预测以北慧生物评估基准日的现有股权结构为框架,不考虑基准日后可能发生的股权变化对其经营状况与盈利能力产生的影响;也不考虑未来可能由于管理层、经营策略和进行扩大性的追加投资等情况;
<八>假设在未来年度北慧生物将不会出现因不可抗力等原因导致公司及其业务发生重大损失的内容,也不考虑付息债务之外的其它不确定性损益;
<九>未来5年期以上的贷款年利率维持在评估基准日时的利率水平;
<十>企业研制的药品能顺利通过临床试验,进行新药注册申请并取得《新药证书》和《药品批准文号》。
对本次评估,公司董事会在进行尽职调查的基础上认为:本次交易标的预期未来各年度收益等重要评估依据、计算模型所采用的折现率等重要评估参数及评估结论具有合理性。
(四)北慧生物最近12个月内的增资情况。
最近12个月内,北慧生物进行了3次增资,分别为:
1、2016年3月,北慧生物的注册资本由1000.00万元增至2016.00万元,由何龙飞以人民币增资5,000.00万元,其中1,016.00万元计入实收资本,3,984.00万元计入资本公积。
2、2016年6月,北慧生物的注册资本由2,016.00万元增至7,759.73万元,由桂林商源植物制品有限公司以货币增资5,743.73万元。
3、2016年6月,北慧生物的注册资本变更为8,000.00万元,由14名自然人股东出资人民币600.675万元。其中240.27万元计入实收资本,360.405万元计入资本公积。
(五)2016年12月9日,北慧生物召开创立大会暨第一次股东大会,审议通过《设立北京慧宝源生物技术股份有限公司的议案》,北慧生物整体变更成为股份公司,改制后北慧生物注册资本仍为8,000.00万元。
四、合作协议的主要内容
2017年2月28日,尖峰药业(甲方或“投资方”)和北慧企管(乙方)、桂林商源(丙方)(乙方和丙方统称“控股股东”)、北慧生物(丁方、标的公司或公司)签订了《关于北京慧宝源生物技术股份有限公司之增资和股份转让协议》、。
(一)《关于北京慧宝源生物技术股份有限公司之增资和股份转让协议》的主要条款有:
<1>投资的前提条件
1.1各方确认,投资方在本协议项下的投资义务(包括持续增加出资和受让股份)以下列全部条件的满足为前提:
1.1.1各方同意并正式签署本协议并生效,包括所有附件内容。
1.1.2标的公司就每一期投资已按照《公司法》、本协议的相关条款完成章程修改。
1.1.3本次交易取得标的公司董事会、股东大会决议通过本协议项下的增资和股份转让事宜,及前述修改后的章程或章程修正案;并且原股东在作出股东大会决议时一并放弃对于本次交易的优先购买权和优先认购权。
1.1.4标的公司及控股股东于本协议附件五中所作出的陈述、保证与承诺在所有重大方面依然真实、准确、完整。
1.1.5开发期内,标的公司的经营或财务状况等方面没有发生重大不利变化(重大不利变化包括曲沙他滨、克拉夫定或中药019/018等新药的开发无法持续或超出附件三新药开发进度计划确定的时间一年,或各期投资上一年度的实际经营业绩未达到控股股东作出的当期业绩承诺50%以上),如果出现上述
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05